Drugs / CC-90005
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02502188 | Jul → Nov 2015 | parapsoriasis | Celgene Corporation | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CC-90005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02502188 ↗ |
| Route | Oral | “following a single oral dose in healthy subjects” NCT02502188 ↗ |